Table 7.
Distribution of Histologically Confirmed Brain and Other Central Nervous System Tumors by WHO Grade and Major Histology Grouping, CBTRUS Statistical Report: NPCR and SEER, 2011-2014
| Histology | Number of newly diagnosed tumors | Histologically Confirmed | Complete WHO grade Information a | Assigned Grade | |||
|---|---|---|---|---|---|---|---|
| Grade I | Grade II | Grade III | Grade IV | ||||
| Tumors of Neuroepithelial Tissue | 87,651 | 89.4% | 84.5% | 10.9% | 14.7% | 13.8% | 60.7% |
| Pilocytic astrocytoma | 4,168 | 92.5% | 85.3% | 92.8% | 6.1% | 0.8% | 0.4% |
| Diffuse astrocytoma | 6,006 | 92.4% | 85.9% | 4.3% | 60.1% | 21.1% | 14.6% |
| Anaplastic astrocytoma | 5,310 | 99.4% | 94.1% | 0.1% | 1.1% | 90.0% | 8.8% |
| Unique astrocytoma variants | 908 | 77.5% | 77.7% | 25.4% | 54.7% | 15.5% | 4.4% |
| Malignant | 619 | 87.1% | 78.7% | 4.2% | 70.0% | 20.0% | 5.7% |
| Non-Malignant | 289 | 57.1% | 74.5% | 98.4% | 1.6% | 0.0% | 0.0% |
| Glioblastoma | 45,613 | 93.1% | 86.3% | 0.2% | 0.2% | 1.0% | 98.7% |
| Oligodendroglioma | 2,924 | 96.3% | 92.8% | 1.6% | 85.3% | 6.5% | 6.5% |
| Anaplastic oligodendroglioma | 1,394 | 99.2% | 95.2% | 0.2% | 3.0% | 87.8% | 9.0% |
| Oligoastrocytic tumors | 2,350 | 99.6% | 95.4% | 0.9% | 51.3% | 39.5% | 8.4% |
| Ependymal tumors | 5,421 | 90.4% | 83.7% | 35.0% | 50.2% | 14.1% | 0.7% |
| Malignant | 3,215 | 94.0% | 87.6% | 2.9% | 74.3% | 21.8% | 1.0% |
| Non-Malignant | 2,206 | 85.0% | 77.4% | 93.5% | 6.3% | 0.1% | 0.1% |
| Glioma malignant, NOS | 5,872 | 32.4% | 49.9% | 23.8% | 27.4% | 21.1% | 27.7% |
| Choroid plexus tumors | 640 | 87.7% | 73.8% | 65.0% | 17.6% | 16.7% | 0.7% |
| Malignant | 105 | 97.1% | 80.4% | 8.5% | 3.7% | 84.1% | 3.7% |
| Non-Malignant | 535 | 85.8% | 72.3% | 78.9% | 21.1% | 0.0% | 0.0% |
| Other neuroepithelial tumors | 78 | 94.9% | 45.9% | 5.9% | 55.9% | 26.5% | 11.8% |
| Malignant | 51 | 100.0% | 33.3% | 5.9% | 17.6% | 52.9% | 23.5% |
| Non-Malignant | 27 | 85.2% | 73.9% | 5.9% | 94.1% | 0.0% | 0.0% |
| Neuronal and mixed neuronal-glial tumors | 3,576 | 93.6% | 61.6% | 79.4% | 15.9% | 3.9% | 0.8% |
| Malignant | 735 | 98.5% | 15.1% | 17.4% | 7.3% | 64.2% | 11.0% |
| Non-Malignant | 2,841 | 92.3% | 74.5% | 82.8% | 16.4% | 0.6% | 0.2% |
| Tumors of the pineal region | 586 | 75.8% | 70.0% | 23.8% | 22.2% | 15.4% | 38.6% |
| Malignant | 319 | 94.7% | 75.2% | 2.2% | 24.7% | 20.3% | 52.9% |
| Non-Malignant | 267 | 53.2% | 59.2% | 82.1% | 15.5% | 2.4% | 0.0% |
| Embryonal tumors | 2,805 | 98.1% | 72.5% | 1.3% | 0.2% | 1.3% | 97.3% |
| Tumors of Cranial and Spinal Nerves | 26,038 | 51.6% | 32.0% | 99.0% | 0.5% | 0.3% | 0.2% |
| Nerve sheath tumors | 26,016 | 51.6% | 32.1% | 99.0% | 0.5% | 0.3% | 0.2% |
| Malignant | 183 | 83.1% | 19.1% | 55.2% | 10.3% | 24.1% | 10.3% |
| Non-Malignant | 25,833 | 51.4% | 32.2% | 99.3% | 0.4% | 0.1% | 0.1% |
| Other tumors of cranial and spinal nerves | 22 | 45.5% | 10.0% | 100.0% | 0.0% | 0.0% | 0.0% |
| Tumors of Meninges | 116,086 | 43.3% | 77.2% | 81.1% | 16.8% | 2.0% | 0.2% |
| Meningioma | 112,582 | 42.0% | 79.0% | 81.3% | 16.9% | 1.7% | 0.1% |
| Malignant | 1,416 | 79.2% | 81.8% | 24.4% | 16.0% | 58.3% | 1.3% |
| Non-Malignant | 111,166 | 41.5% | 78.9% | 82.7% | 17.0% | 0.2% | 0.1% |
| Mesenchymal tumors | 1,074 | 71.2% | 49.3% | 8.2% | 48.5% | 37.7% | 5.6% |
| Primary melanocytic lesions | 95 | 91.6% | 11.5% | 60.0% | 20.0% | 10.0% | 10.0% |
| Other neoplasms related to the meninges | 2,335 | 92.2% | 50.9% | 98.8% | 0.8% | 0.1% | 0.3% |
| Lymphomas and Hematopoietic Neoplasms | 6,186 | 93.9% | 4.6% | 100.0% | 0.0% | 0.0% | 0.0% |
| Lymphoma | 5,991 | 94.0% | 4.7% | 100.0% | 0.0% | 0.0% | 0.0% |
| Other hematopoietic neoplasms | 195 | 90.3% | 0.6% | 100.0% | 0.0% | 0.0% | 0.0% |
| Germ Cell Tumors and Cysts | 1,174 | 81.9% | 3.7% | 19.4% | 16.7% | 13.9% | 50.0% |
| Germ cell tumors, cysts and heterotopias | 1,174 | 81.9% | 3.7% | 19.4% | 16.7% | 13.9% | 50.0% |
| Malignant | 790 | 89.0% | 4.6% | 9.4% | 16.7% | 15.6% | 56.3% |
| Non-Malignant | 384 | 67.2% | 1.6% | 100.0% | 0.0% | 0.0% | 0.0% |
| Tumors of Sellar Region | 52,116 | 51.2% | 7.5% | 96.5% | 2.1% | 0.3% | 1.2% |
| Tumors of the pituitary | 49,750 | 49.7% | 4.8% | 94.8% | 2.8% | 0.4% | 1.9% |
| Malignant | 143 | 65.0% | 7.5% | 71.4% | 0.0% | 0.0% | 28.6% |
| Non-Malignant | 49,607 | 49.6% | 4.8% | 94.9% | 2.9% | 0.4% | 1.8% |
| Craniopharyngioma | 2,366 | 83.6% | 40.3% | 99.0% | 0.9% | 0.1% | 0.0% |
| Unclassified Tumors | 16,622 | 17.5% | 6.3% | 66.7% | 7.1% | 11.5% | 14.8% |
| Hemangioma | 4,981 | 28.4% | 3.3% | 95.7% | 0.0% | 2.1% | 2.1% |
| Neoplasm, unspecified | 11,553 | 12.6% | 8.7% | 55.9% | 10.2% | 14.2% | 19.7% |
| Malignant | 5,303 | 9.0% | 10.9% | 17.3% | 7.7% | 28.8% | 46.2% |
| Non-Malignant | 6,250 | 15.7% | 7.6% | 82.7% | 12.0% | 4.0% | 1.3% |
| All other | 88 | 45.5% | 22.5% | 66.7% | 0.0% | 22.2% | 11.1% |
| TOTAL | 305,873 | 58.4% | 62.7% | 40.5% | 14.6% | 8.9% | 36.1% |
| Malignant | 96,062 | 85.3% | 77.8% | 6.7% | 14.7% | 15.4% | 63.2% |
| Non-Malignant | 209,811 | 46.0% | 49.8% | 85.2% | 14.4% | 0.3% | 0.1% |
aCompleteness is defined as having an assigned code that corresponds with a WHO grade as defined by the American Joint Commission on Cancer’s Collaborative Staging schema.
Abbreviations: CBTRUS, Central Brain Tumor Registry of the United States; CNS, central nervous system; NPCR, National Program of Cancer Registries; SEER, Surveillance, Epidemiology, and End Results program; WHO, World Health Organization.